(S046) Prognosis for Patients With Metastatic Breast Cancer Who Achieve ‘No-Evidence-of-Disease’ Status After Systemic or Local Therapy

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Achieving NED status correlates strongly with outcome in MBC, making this a potentially valuable short-term clinical trial endpoint akin to pathologic complete response. MBC patients who attain NED have prolonged survival, with perhaps up to one-third achieving complete remission.

Andrew J. Bishop, Joe Ensor, Stacy L. Moulder, Simona F. Shaitelman, Mark A. Edson, Gary J. Whitman, Sandra Bishnoi, Karen E. Hoffman, Michael C. Stauder, Vicente Valero, Thomas A. Buchholz, Naoto T. Ueno, Gildy Babiera, Wendy A. Woodward; UT MD Anderson Cancer Center; Rice University

PURPOSE/OBJECTIVES: Newer systemic therapy regimens are more commonly associated with complete or near-complete radiographic response in patients with metastatic breast cancer (MBC). We investigated outcomes for patients with MBC with no evidence of disease (NED) after treatment and identified factors that were predictive of outcome once NED status was achieved.

MATERIALS AND METHODS: We reviewed 570 patients with MBC consecutively treated between January 2003 and December 2005. NED was defined as a complete metabolic response by positron emission tomography (PET) and/or sclerotic healing of bone metastases on computed tomography (CT) or magnetic resonance imaging (MRI). Median follow-up was 27 months (range: 0–134 mo) for all patients and 100 months (range: 14–134 mo) for NED patients. The Kaplan-Meier method estimated overall survival (OS) and progression-free survival (PFS); log-rank tests assessed for equality among groups. Cox proportional hazard models were used. Estimated hazard ratios (HRs) are reported.

RESULTS: The 3- and 5-year OS rates for the entire group were 44% and 24% compared with 96% and 78%, respectively, for the NED subset (n = 90, 16%). Patients who attained NED status had a longer median survival (112 vs 24 months; P < .001), which correlated strongly with survival on multivariate analysis (P < .001; HR = 0.15). Several other factors were also associated with more favorable survival on multivariate analysis, including presenting with de novo MBC (P < .001; HR = 0.60) and distant metastases involving only bone (P < .001; HR = 0.52) or only lung (P < .001; HR = 0.47). Patients who developed NED were more likely to have a normal body mass index (BMI) (P < .001), have either estrogen receptor (ER)+ or human epidermal growth factor receptor 2 (HER2)+ tumors (P < .001), have single sites of metastasis (P < .001), and present with de novo MBC (P = .04) when compared with the non-NED group. For patients with NED, the 3- and 5-year PFS rates (after NED) were 54% and 38%, respectively, with a median NED duration of 41 months (range: 0–115 mo). The only characteristics associated with PFS after NED were receptor status (HER2+ 58 mo vs ER+ 35 mo vs TNBC 13 mo; P = .02), inflammatory breast cancer at presentation (28 mo vs 45 mo; P = .02), and trastuzumab use (73 mo vs 31 mo; P = .02). Of the 63 patients who had disease progression, 20 achieved a second NED status. Ultimately, 31 patients (34%) with NED remained in remission at last follow-up.

CONCLUSIONS: Achieving NED status correlates strongly with outcome in MBC, making this a potentially valuable short-term clinical trial endpoint akin to pathologic complete response. MBC patients who attain NED have prolonged survival, with perhaps up to one-third achieving complete remission.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content